Lumos Diagnostics Requests Trading Halt
Key points
- Company requests trading halt pending announcement on FDA response to FebriDx CLIA waiver application
- Trading halt to remain in place until earlier of market open on March 27 or announcement release
- Company expects to make announcement before market open on March 27
Full summary
Lumos Diagnostics Holdings Ltd (ASX: LDX) has requested an immediate trading halt on its securities pending an announcement to the market in relation to an update on the FDA response to the FebriDx CLIA waiver application. The trading halt will remain in place until the earlier of the commencement of normal trading on Friday, 27 March 2026, or the release of the announcement to the market. The company expects to make the announcement before the market opens on Friday, 27 March 2026. Lumos Diagnostics has requested the trading halt to assist the company in managing its continuous disclosure obligations as it expects to make an announcement to the market regarding the stated purpose.
Summary generated by a large language model. Please interpret with care.